Reducing time to market for new drug introductions has never been more crucial. Getting new drugs approved is a long and wearisome process that leaves no room for mistakes, as they can be costly. AI can dramatically help speed up these processes, while improving accuracy.
Generating Clinical Study Reports (CSRs) is a very tedious step before submitting new drugs for approval, taking weeks and in some cases months to introduce fully to market. Automating CSR writing with AI-based technologies such as machine learning and Natural Language Processing saves significant time, reducing report writing times by an average of 30%.
In the recorded webinar hosted by Emmanuel Walckenaer, CEO of Yseop and pharma expert Jean Luc Schmidt to learn how pharmaceutical organizations are harnessing AI to solve some of the challenges of introducing new drugs.
In our discussion with Cognizant, we covered a wide range of topics, including:
Common challenges pharmaceutical companies face when launching a new drug
How to automate Clinical Study Report (CSR) writing with AI-based technologies
The importance of a global approach to streamline workflows through intelligent automation
And discover a demo Augmented Medical Writer during.
With the participation of: